Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0331 • ACR Convergence 2021
Urinary MicroRNAs as Systemic Lupus Erythematosus Biomarkers and Its Potential for Accurate Assessment of Disease Severity
Hiroki Yamaguchi¹, Yoriko Ando¹, Mika Mizunuma¹, Masamichi Inami², Kenichi Suzumura² and Yuki Ichikawa¹, ¹Craif Inc., Nagoya, Japan, ²Analysis & Pharmacokinetics Research Labs., Astellas Pharma Inc., Tsukuba, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by autoantibody production, immune complex deposition, and heterogeneous clinical manifestations affecting many organs, including…
Abstract Number: 0348 • ACR Convergence 2021
The New EULAR/ ACR 2019 SLE Classification Criteria: A Predictor of Long-term Outcomes
Laura Whittall-Garcia¹, Dafna Gladman², Murray Urowitz³, Jiandong Su⁴, Zahi Touma⁵ and Sindhu Johnson⁶, ¹University of Toronto, University Health Network, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University of Toronto, Mississauga, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: We recently demonstrated that a EULAR/ACR classification Criteria score ≥ 20 predicts a higher disease activity throughout the first 5 years after diagnosis. Given…
Abstract Number: 0531 • ACR Convergence 2021
Molecular Heterogeneity Between Different Classes of Lupus Nephritis as Revealed by Kidney Biopsy Proteomics
Asmaa AbuMaziad¹, Abhimanyu Amarnani² and Ram Singh³, ¹University of California Los Angeles, Los Angeles, CA, ²Los Angeles County + University of Southern California, Los Angeles, CA, ³University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Lupus nephritis (LN) causes substantial morbidity and mortality. LN is histopathologically divided into six classes, which currently serves as the basis for making treatment…
Abstract Number: 0623 • ACR Convergence 2021
Intervention to Improve SLE Medication Adherence
Kai Sun¹, Amanda Eudy², Jennifer Rogers¹, Rebecca Sadun², Lisa Criscione-Schreiber¹, Jayanth Doss², Mithu Maheswaranathan¹, Ann Barr², Lena Eder³, Amy Corneli¹, Hayden Bosworth² and Megan Clowse⁴, ¹Duke University School of Medicine, Durham, NC, ²Duke University, Durham, NC, ³Duke University Medical Center, Durham, NC, ⁴Duke University, Chapel Hill, NC
Background/Purpose: Medication nonadherence is as high as 80% among SLE patients and leads to higher morbidity, mortality, and healthcare costs. Both the under-recognition of nonadherence…
Abstract Number: 0855 • ACR Convergence 2021
Asymptomatic Coronary Artery Disease Assessed by Coronary Computed Tomography in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis
Claudia Mendoza-Pinto¹, Pamela Munguía-Realpozo², Karla Godinez-Bolaños², Mario García-Carrasco², Ivet Etchegaray-Morales² and Socorro Méndez-Martínez³, ¹Instituto Mexicano del Seguro Social, San Andres Cholula, Mexico, ²Benemérita Universidad Autónoma de Puebla, Puebla, Mexico, ³Instituto Mexicano del Seguro Social, Puebla, Mexico
Background/Purpose: To date, the prevalence and prognosis of coronary artery disease (CAD) according to the coronary calcium score (CCS) and coronary artery calcification (CAC) using…
Abstract Number: 0872 • ACR Convergence 2021
Lack of Association Between Cognitive Test Performance and Cognitive Symptoms in Systemic Lupus Erythematosus (SLE)
Sudha Raghunath¹, Yifat Glikmann-Johnston¹, Emma Guymer¹, Eric Morand², Julie Stout¹ and Alberta Hoi³, ¹Monash University, Melbourne, Australia, ²School of Clinical Sciences at Monash Health, Monash University Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre Clayton, Melbourne, Australia, ³Department of Rheumatology, Monash Health & Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia
Background/Purpose: Cognitive dysfunction (CD) is reported to affect approximately 40% of SLE patients (1). Mood disorders have been associated with both cognitive symptoms and cognitive…
Abstract Number: 0889 • ACR Convergence 2021
Association of Subjective Cognitive Report Using PDQ-20 to a Neuropsychological Battery in a Cohort of SLE Patients
Ambika Gupta¹, Sindhu Johnson², Jiandong Su³, Andrea Knight⁴, Juan Diaz-Martinez⁵, Kathleen Bingham⁶, Mahta Kakvan³, Maria Tartaglia³, Lesley Ruttan⁶, Joan Wither³, May Choi⁷, Marvin Fritzler⁸, Dennisse Bonilla³, Dorcas Beaton⁹, Patricia Katz¹⁰, Robin Green³ and Zahi Touma¹, ¹University of Toronto, Mississauga, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Hospital for Sick Children, Toronto, ON, Canada, ⁵UHN, Toronto, ON, Canada, ⁶University of Toronto, University Health Network, Toronto, ON, Canada, ⁷Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁸University of Calgary, Calgary, AB, Canada, ⁹Institute for Work & Health, Toronto, ON, Canada, ¹⁰University of California San Francisco, San Francisco, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) can lead to a number of neuropsychiatric manifestations including cognitive impairment (CI). Previous meta-analyses have reported the prevalence of CI…
Abstract Number: 0994 • ACR Convergence 2021
Role of SLE Associated Cytokines in Generation of Mature Neutrophils
Neelakshi R. Jog, Julia Nguyen and Judith James, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by autoantibody production and periods of elevated disease activity. Recent studies indicate that along…
Abstract Number: 1161 • ACR Convergence 2021
Patient Preferences for Hydroxychloroquine in Systemic Lupus (SLE)
Jennifer Dollinger¹, Celline Brasil¹, Marcus Wong¹, Glen Hazlewood², Ryan Dollinger¹, Wendy Singer³, Christian Pineau⁴, Evelyne Vinet⁵, Ann Clarke², Jennifer Lee¹ and Sasha Bernatsky⁴, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²University of Calgary, Calgary, AB, Canada, ³McGill University Health Centre, Montréal, QC, Canada, ⁴McGill University, Montréal, QC, Canada, ⁵McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Although hydroxychloroquine (HCQ) has been shown to reduce SLE flares, concerns exist regarding side effects from long-term use. Very little information is available on…
Abstract Number: 1269 • ACR Convergence 2021
The Burden of Systemic Lupus Erythematosus Patients in the United States – Evidence from the Medical Expenditure Panel Survey (2016-2018)
Shannon Grabich¹, Eilleen Farrelly², Robert Ortmann³, Michael Pollack⁴ and Sandra Sze-jung Wu⁴, ¹Xcenda, Durham, NC, ²Xcenda, Carrollton, TX, ³AstraZeneca, Greenwood, IN, ⁴AstraZeneca, Wilmington, DE
Background/Purpose: Due to the heterogeneity of systemic lupus erythematosus (SLE), clinical characteristics, quality of life (QOL), social determinant of health (SDOH), health care utilization (HRU),…
Abstract Number: 1285 • ACR Convergence 2021
Major Determinants of Prolonged Remission in Systemic Lupus Erythematosus: Retrospective Study over a 41-Year Period
Goncalo Durao-Carvalho¹, Raquel Fernandez², Bethan Goulden³, Filipa Farinha⁴ and David Isenberg⁵, ¹Servico de Medicina Interna, Centro Hospitalar do Oeste – Unidade de Caldas da Rainha, Caldas da Rainha, Portugal, Caldas da Rainha, Portugal, ²Servicio de Medicina Interna, Hospital Universitario de Ourense, Ourense, Spain, ³Department of Rheumatology, University College London Hospitals, London, United Kingdom, ⁴Department of Rheumatology, University College London Hospitals and Centre for Rheumatology, University College London, London, United Kingdom, ⁵Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Disease activity is a major determinant of mortality whereas prolonged remission contributes to improving health outcomes in SLE patients (pts). Remission is thus a…
Abstract Number: 1303 • ACR Convergence 2021
Associations Between Early Changes in Circulating B Cell Subsets and Severe Flare in Systemic Lupus Erythematosus – Results from Three Phase III Trials of Belimumab
Ioannis Parodis¹, Alvaro Gomez², Julius Lindblom², Alexander Borg², Sharzad Emamikia² and Mariele gatto³, ¹Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden and Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden, ²Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ³Department of Rheumatology, University of Padua, Padua, Italy
Background/Purpose: Belimumab is the only approved targeted treatment for systemic lupus erythematosus (SLE). Identification of early predictors of response or non-response to therapy is imperative…
Abstract Number: 1464 • ACR Convergence 2021
Ambulatory Fetal Heart Rate Monitoring (FHRM) to Surveil Pregnancies at Risk for Congenital Heart Block
Mala Masson¹, Colin Phoon¹, Elena Sinkovskaya², Lisa Howley³, Ruben Acherman⁴, Majd Makhoul⁵, Nelangi Pinto⁶, Miao Chang¹, Robert Clancy⁷, Bailey Drewes⁸, Bettina Cuneo⁹ and Jill Buyon⁷, ¹NYU Langone Health, New York, NY, ²East Virginia Medical School, Norfolk, ³Children's Hospitals and Clinics of Minnesota, Minneapolis, MN, ⁴Sunrise Children's Hospital, Las Vegas, NV, ⁵UK Kentucky Children's Hospital, Lexington, KY, ⁶University of Utah, Salt Lake City, UT, ⁷NYU Grossman School of Medicine, New York, NY, ⁸CU Anschutz Medical Campus, Aurora, ⁹Children's Hospital Colorado, Aurora, CO
Background/Purpose: Congenital Heart Block (CHB) complicates 2% of anti-Ro/SSA antibody positive pregnancies and carries substantial perinatal morbidity and mortality. Almost all survivors require lifelong pacing.…
Abstract Number: 1497 • ACR Convergence 2021
Kidney Disease in Lupus Patients Is Linked to Monocytes’ Aberrant Spliceosome and Altered Expression of IFN-Response Related Genes
Chary Lopez-Pedrera¹, Alejandra Patiño-Trives², Alejandro Ibañez-Costa³, Maria Luque-Tevar², Iván Arias de la Rosa⁴, Desiree Ruiz⁵, Pedro Seguí-Azpilicueta⁵, Mario Espinosa⁵, Rosa Ortega⁵, Nuria Barbarroja⁴, Justo P Cataño³, Raul Luque³, Maria Angeles Aguirre¹ and Carlos Pérez-Sánchez⁶, ¹IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ²Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, ³IMIBIC, Department of Cell Biology, Physiology and Immunology, University of Cordoba, Córdoba, Spain, ⁴University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ⁵IMIBIC, Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ⁶IMIBIC, Córdoba, Spain
Background/Purpose: The present study aimed at: 1- Identifying altered SLE monocytes transcriptomic signatures linked to the immune response and its association with clinical features. 2-…
Abstract Number: 1622 • ACR Convergence 2021
Mind the Gap: The Experience of Adolescents in a Rheumatology Transition Clinic
Claire Fine¹, Karen Beattie¹, Tania Cellucci², Liane Heale¹, Mark Matsos¹, Stephanie Garner¹ and Michelle Batthish¹, ¹McMaster University, Hamilton, ON, Canada, ²McMaster Children's Hospital, Hamilton, ON, Canada
Background/Purpose: The transition from pediatric to adult healthcare is a critical time for the wellbeing of patients with chronic illness including rheumatologic disease. Low patient…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].